Skip to main content
. 2023 Mar 24;13:1139940. doi: 10.3389/fonc.2023.1139940

Table 3.

Comparisons of stage III NSCLC patients with adenocarcinoma subtype who received surveillance brain MRI and those who did not.

  No Surveillance brain MRI
(n = 79)
Surveillance brain MRI
(n = 17)
Developed BrMs: number (%)
Yes 25 (31.6%) 4 (23.5%)
No 54 (68.4%) 13 (76.5%)
BrMs: number (%)
Symptomatic 12 (48.0%) 3 (75.0%)
Asymptomatic 13 (52.0%) 1 (25.0%)

BrMs, brain metastases.